Target group enlargement is expected to increase sales revenue
Martinsried/Munich, 05. December 2013. Medigene AG (MDG, Frankfurt, Prime Standard) announces that its drug Veregen® for the treatment of genital warts will be marketed by the company's new partner Taurus Pharma GmbH, Germany beginning in January 2014. Medigene, the current partner Abbott, and the pharmaceutical company Taurus Pharma GmbH have jointly agreed on this. The new marketing partner will add the dermatologists, who represent an important group of specialists to treat this skin disease, to Veregen® target group. The partners anticipate that this will bring about an increase in sales of the prescription drug. In Austria and Switzerland, Veregen® will continue to be distributed by Medigene's partner Abbott in the future.
Dr. Frank Mathias, Chief Executive Officer of Medigene, comments: "The new partnership is a gain for Veregen® and beneficial for the affected patients. Thanks to many years of experience in both fields, Taurus will sell our drug not only to gynecologists, as has been the case until now, but equally to dermatologists. This will further expand the reach for Veregen®."
Klaus Seliger, Managing Director of Taurus Pharma GmbH, adds: "Veregen® ideally adds to both our dermatology as well as the gynecology portfolios. Hence Veregen® will play a key role in our sales activities. We look forward to providing as many patients as possible with this innovative and reliable drug, by extensively informing the two major physician groups treating patients that suffer from external genital warts about the efficacious therapeutic option Veregen®."
Apart from the German-speaking countries, Veregen® is also available in the USA (distributed by Fougera), Spain (Bial), Serbia (Pharmanova), the Netherlands (Will-Pharma), and Taiwan (SynCore) and has been approved in a number of additional countries. Medigene expects the launch of Veregen® in other countries within the next few months. Several marketing partnership agreements have been concluded in Europe, Asia, and America. Medigene is planning to continue this global licensing strategy to further tap the product's market potential.
Veregen®: Veregen®, a topical treatment for external genital or perianal warts, contains a concentrate of catechins with a complex defined composition extracted from green tea leaves. In its current treatment guidelines for sexually transmitted diseases, the US Center for Disease Control and Prevention recommends Sinecatechins 15% ointment (Veregen®) as a possible option for treating genital warts. In addition, Sinecatechins 10% & 15% ointments (Veregen®) have been included in the current European guideline on the treatment of genital warts, the 2012 European Guideline for the Management of Anogenital Warts.
Taurus Pharma: Taurus Pharma GmbH, headquartered in Bad Homburg vor der Höhe, Germany, has been selling pharmaceuticals in Germany for more than 25 years. As a member of the Poli Group Holding, Taurus Pharma benefits from the research and development work done by this globally operating group of companies. Shareholders and employees are working on adding high-quality products that provide true help for the patients in the treatment of their diseases. For this purpose, Taurus Pharma develops and distributes an attractive range of prescription and OTC drugs. The company's focus is on gynecology and dermatology. For more detailed information, please visit www.tauruspharma.de.
Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and Veregen® are registered trademarks of Medigene AG. Polyphenon E® is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or licensed in select locations only.
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.